Xue-Song Sun

机构：Harbin Medical University, Sun Yat-sen University, Second Affiliated Hospital of Harbin Medical University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China

发表论文 73 篇 · 总被引 1284 次 · h-index 19

代表论文

• Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial (2023 · Nature Communications · 被引 50)
• Concurrent chemoradiotherapy followed by adjuvant cisplatin–gemcitabine versus cisplatin–fluorouracil chemotherapy for N2–3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial (2023 · The Lancet Oncology · 被引 41)
• Identification of potential immune-related hub genes in Parkinson’s disease based on machine learning and development and validation of a diagnostic classification model (2023 · PLoS ONE · 被引 10)
• Optimizing the prediction of sepsis-associated encephalopathy with cerebral circulation time utilizing a nomogram: a pilot study in the intensive care unit (2024 · Frontiers in Neurology · 被引 9)
• Paclitaxel liposome, cisplatin and 5-fluorouracil-based induction chemotherapy followed by de-escalated intensity-modulated radiotherapy with concurrent cisplatin in stage IVA–IVB childhood nasopharyngeal carcinoma in endemic area: a phase II, single-arm trial (2023 · The Lancet Regional Health - Western Pacific · 被引 9)
• Head and neck MRI-based T stage and [18F]FDG PET/CT-based N/M stage improved prognostic stratification in primary nasopharyngeal carcinoma (2023 · European Radiology · 被引 8)